VoxCell, a Canadian biotechnology company advancing high-resolution, vascularized 3D tissue models, today announced the appointment of Graham Craig as Chief Commercial Officer (CCO). The hire comes as the company sets its sights on growth driven by increasing demand for predictive, human-relevant non-clinical models.
VoxCell's vascularized 3D tissue models replicate key features of the human vascular microenvironment. These models enable the evaluation of drug penetration, extravasation, efficacy, and vascular toxicity behaviors in a single physiologically relevant system. The model provides a solution to the limitations and low translation success rates of traditional animal models, ethical concerns, and recent regulatory shifts.
Craig joins VoxCell from clinical-stage biotechnology company, AbCellera. He brings more than 18 years of experience in commercialization and strategic partnerships across the pharmaceutical and biotech sectors. In his new role, his key responsibilities will be to lead VoxCell's commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of New Approach Methodologies (NAMs).
"Craig is a commercial leader with deep experience translating complex life-science platforms into customer value and scalable revenue. As regulators move to modernize nonclinical testing expectations and the industry increases investment in NAMs, VoxCell is well-positioned to help drug developers generate more human-relevant data earlier. Craig's leadership will strengthen our ability to serve pharmaceutical companies, CROs, and research institutions as they adapt to this transition."
At AbCellera, Craig was Director of Corporate Development, where he was responsible for the identification, evaluation, and integration of new enabling technologies. Before this, he worked for STEMCELL Technologies Inc, leading several high-profile corporate initiatives, and spent seven years as a commercial strategy consultant for IQVIA Inc., supporting pharmaceutical companies across Europe, Asia, and North America.
"VoxCell is addressing a clear and growing market need for the provision of preclinical translation through models that more closely reflect human biology. With increasing regulatory and industry alignment on NAMs, our vascularized tissue models offer a compelling path to quickly generate decision-enabling data, helping teams prioritize the right programs earlier and reduce late-stage failure risk."
"It's an exciting time to join the company as we focus on expanding access to the platform through partnerships and customer programs globally."
Recent policy developments underscore growing support for NAMs. The FDA recently outlined a stepwise approach to reduce reliance on animal testing in preclinical testing and allow alternative non-animal models for new drug and biological product applications. This was reinforced recently by reports of the first FDA-cleared Investigational New Drug (IND) application based on data from a human vascularized organoid-based model.